Dépôt numérique

Dimethylbenz(a)anthracene-induced mammary tumorigenesis in mice

Plante, Isabelle ORCID: https://orcid.org/0000-0003-2080-6450 (2020). Dimethylbenz(a)anthracene-induced mammary tumorigenesis in mice In: Carcinogen-driven mouse models of oncogenesis. Methods in Cell Biology, 163 (163). Academic Press, Cambridge, MA, p. 21-44.

Ce document n'est pas hébergé sur EspaceINRS.


Every year, over 2 million women are diagnosed with breast cancer. Although considerable progress was made within the last years in cancer prevention, diagnosis and treatment, breast cancer is still responsible for over 600,000 of deaths per year. Over the years, numerous mouse models have been developed to understand breast cancer etiology and progression. Among those, mammary carcinomas induced by carcinogen, such as 7,12-dimethylbenz[a]anthracene (DMBA), has been widely used. Generally, 30–70% of mice exposed to 4–6 weekly doses of 1 mg of DMBA during the peripubertal period (4–10 weeks of age) will develop mammary tumors within 150–200 days after the first exposure, that sometime metastasize to the lungs. As a result, DMBA-induced tumorigenesis is thought to be an accurate and relevant model to study breast cancer as it closely mimics this multistep process. This chapter presents the typical protocol used in mice to induce mammary gland tumors using DMBA. The influence of the number of doses and the total burden of DMBA given, as well as of the age and strain of the mice on mammary gland incident and on tumor onset are discussed. The current knowledge regarding mechanisms involved in DMBA-induced tumorigenesis is also presented.

Type de document: Chapitre de livre
Mots-clés libres: Breast cancer; Dimethylbenz(a)anthracene; Mammary gland; Peripubertal; Protocol; Tumorigenesis
Centre: Centre INRS-Institut Armand Frappier
Date de dépôt: 20 juill. 2021 04:11
Dernière modification: 15 févr. 2022 21:19
URI: https://espace.inrs.ca/id/eprint/11719

Actions (Identification requise)

Modifier la notice Modifier la notice